Cargando…

Amino Acid-Metabolizing Enzymes in Advanced High-Grade Serous Ovarian Cancer Patients: Value of Ascites as Biomarker Source and Role for IL4I1 and IDO1

SIMPLE SUMMARY: Ovarian cancer is the most lethal gynecological malignancy in the United States. Despite the success of immunotherapy for treatment of various cancer types, its impact on ovarian cancer is restrained by a highly immunosuppressive tumor microenvironment. We aimed to evaluate the contr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grobben, Yvonne, den Ouden, Judith E., Aguado, Cristina, van Altena, Anne M., Kraneveld, Aletta D., Zaman, Guido J. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913486/ https://www.ncbi.nlm.nih.gov/pubmed/36765849 http://dx.doi.org/10.3390/cancers15030893

Ejemplares similares

Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites
por: den Ouden, Judith E., et al.
Publicado: (2020)

Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer
por: Hoffmann, Inga, et al.
Publicado: (2023)

Morphological and Immunocytochemical Characterization of Tumor Spheroids in Ascites from High-Grade Serous Carcinoma
por: Miceska, Simona, et al.
Publicado: (2023)

The prognostic significance of tumor-immune microenvironment in ascites of patients with high-grade serous carcinoma
por: Miceska, Simona, et al.
Publicado: (2023)

Ascitic Senescent T Cells Are Linked to Chemoresistance in Patients With Advanced High-Grade Serous Ovarian Cancer
por: Zhang, Jie, et al.
Publicado: (2022)

Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2
por: Lee, Young-Kwan, et al.
Publicado: (2014)

A single-cell landscape of pre- and post-menopausal high-grade serous ovarian cancer ascites
por: Chen, Wenying, et al.
Publicado: (2023)

Iminosugar Amino Acid idoBR1 Reduces Inflammatory Responses in Microglia
por: Olajide, Olumayokun A., et al.
Publicado: (2022)

Impact of IDO1 and IDO2 on the B Cell Immune Response
por: Merlo, Lauren M. F., et al.
Publicado: (2022)

IL-22 and IDO1 Affect Immunity and Tolerance to Murine and Human Vaginal Candidiasis
por: De Luca, Antonella, et al.
Publicado: (2013)

IL-27 induces the expression of IDO and PD-L1 in human cancer cells
por: Carbotti, Grazia, et al.
Publicado: (2015)

Molecular Profiling and Clinical Outcome of High-Grade Serous Ovarian Cancer Presenting with Low- versus High-Volume Ascites
por: Feigenberg, Tomer, et al.
Publicado: (2014)

IL4i1 and IDO1: Oxidases that control a tryptophan metabolic nexus in cancer
por: Zeitler, Leonie, et al.
Publicado: (2023)

Natural history of grade 1 ascites in patients with liver cirrhosis
por: Theodorakopoulos, Theodoros, et al.
Publicado: (2021)

Indoleamine 2,3‐dioxygenase 1 (IDO1): an up‐to‐date overview of an eclectic immunoregulatory enzyme
por: Pallotta, Maria Teresa, et al.
Publicado: (2021)

Amyloid β neurotoxicity is IDO1–Kyn–AhR dependent and blocked by IDO1 inhibitor
por: Duan, Zhenzhen, et al.
Publicado: (2020)

Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
por: Merlo, Lauren M. F., et al.
Publicado: (2020)

Stress hormones are associated with inflammatory cytokines and attenuation of T-cell function in the ascites from patients with high grade serous ovarian cancer
por: Aquino-Acevedo, Alexandra N., et al.
Publicado: (2022)

Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO
por: Kim, Minah, et al.
Publicado: (2021)

Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keynurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia
por: Chilosi, Marco, et al.
Publicado: (2022)

Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans
por: Napolioni, Valerio, et al.
Publicado: (2019)

Cytology of peritoneal implants of borderline serous tumor of ovaries in ascitic fluid
por: Sharma, Sudha, et al.
Publicado: (2021)

Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas
por: Arias-Diaz, Andrea Estrella, et al.
Publicado: (2023)

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
por: Xu, Xia, et al.
Publicado: (2016)

DNA Repair Protein HELQ and XAB2 as Chemoresponse and Prognosis Biomarkers in Ascites Tumor Cells of High-Grade Serous Ovarian Cancer
por: Zhu, Fang, et al.
Publicado: (2022)

Clinical significance of CD8‐positive lymphocytes on tumor cell clusters of ascites cell block in ovarian high‐grade serous carcinoma
por: Iwahashi, Hideki, et al.
Publicado: (2022)

IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cells
por: Nawas, Afshan Fathima, et al.
Publicado: (2023)

Indoleamine 2,3‐dioxygenase (IDO)‐1 and IDO‐2 activity and severe course of COVID‐19
por: Guo, Lihui, et al.
Publicado: (2022)

Immunological Relevance of the Coevolution of IDO1 and AHR
por: Jaronen, Merja, et al.
Publicado: (2014)

IDO1 is an Integral Mediator of Inflammatory Neovascularization
por: Mondal, Arpita, et al.
Publicado: (2016)

Concurrent Primary Peritoneal Low-Grade Serous Carcinoma and Endometrial High-Grade Serous Carcinoma
por: Lockyer, Megan G., et al.
Publicado: (2015)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

Soluble osteopontin concentrations in serum and ascites of women with advanced serous ovarian cancer
por: Černe, Katarina, et al.
Publicado: (2012)

The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma
por: Stronach, Euan A., et al.
Publicado: (2015)

IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
por: Lee, Alexander, et al.
Publicado: (2014)

Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells
por: Marttila, Saara, et al.
Publicado: (2011)

Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use
por: Arinola, Ganiyu Olatunbosun, et al.
Publicado: (2023)

(Acetylacetonato)dibromido[2,2-diphenylhydrazin-1-ido(1−)][2,2-diphenylhydrazin-1-ido(2−)]molybdenum(VI)
por: Bustos, Carlos, et al.
Publicado: (2011)

Correction: IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
por: Lee, Alexander, et al.
Publicado: (2015)

Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients
por: Cao, Tingming, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tds2vm72cuj9e81ger23lf1ail